Trabectedin API Manufacturers
compare suppliers & get competitive offers
Filters
Reset
Selected filters:
Type
Production region
Qualifications
To view suppliers for this material, you need to be logged in first.
This is because of international laws regarding narcotic materials. Furthermore, the contents of this page are only accessible if you are professionaly active in the pharmaceutical industry. In case you are, it is possible to register on our platform, and after your account is approved by our team you will be able to view suppliers and send your request.
Looking for Trabectedin API 114899-77-3?
- Description:
- Here you will find a list of producers, manufacturers and traders of Trabectedin. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Trabectedin
- Synonyms:
- Ecteinascidin 743
- Cas Number:
- 114899-77-3
- DrugBank number:
- DB05109
- Unique Ingredient Identifier:
- ID0YZQ2TCP
About Trabectedin
Want to know more about Trabectedin? Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate Ecteinascidia turbinata and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma.
It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the USA Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
You can ask the supplier for more technical information about the product.
Trabectedin is a type of Oncolytics
Oncolytics, as a subcategory of pharmaceutical active pharmaceutical ingredients (APIs), refers to compounds specifically designed to combat cancer cells. These powerful substances play a crucial role in the development of targeted cancer therapies. Oncolytic APIs are engineered to selectively target and destroy cancer cells while sparing healthy cells, minimizing potential side effects.
The efficacy of oncolytic APIs lies in their ability to disrupt cancer cell growth and induce cell death through various mechanisms. These APIs can directly target specific molecular pathways or receptors that are overexpressed or mutated in cancer cells, inhibiting their growth and proliferation. Additionally, oncolytic APIs can stimulate the immune system to recognize and eliminate cancer cells, harnessing the body's natural defenses against cancer.
The development of oncolytic APIs involves rigorous research and testing to ensure safety and efficacy. Pharmaceutical companies employ advanced technologies and methods to synthesize and optimize these compounds. They undergo preclinical and clinical trials to evaluate their therapeutic potential, dosing, and side effects.
Oncolytic APIs offer great promise in the field of cancer treatment, providing novel therapeutic options for patients. By precisely targeting cancer cells, they have the potential to enhance treatment outcomes and improve patient survival rates. Ongoing research and development in oncolytics continue to expand our understanding of cancer biology and revolutionize cancer treatment strategies.
Trabectedin (Oncolytics), classified under Anticancer drugs
Anticancer drugs belong to the pharmaceutical API (Active Pharmaceutical Ingredient) category designed specifically to combat cancer cells. These powerful medications play a crucial role in cancer treatment and are developed to target and destroy cancerous cells, preventing their growth and spread.
Anticancer drugs are classified based on their mode of action and can include various types such as chemotherapy drugs, targeted therapy drugs, immunotherapy drugs, and hormonal therapy drugs. Chemotherapy drugs work by interfering with the cell division process, thereby inhibiting the growth of cancer cells. Targeted therapy drugs, on the other hand, are designed to attack specific molecules or genes involved in cancer growth, minimizing damage to healthy cells. Immunotherapy drugs stimulate the body's immune system to recognize and destroy cancer cells. Hormonal therapy drugs are used in cancers that are hormone-dependent, such as breast or prostate cancer, to block the hormones that fuel cancer cell growth.
These APIs are typically synthesized through complex chemical processes in state-of-the-art manufacturing facilities. Stringent quality control measures ensure the purity, potency, and safety of these drugs. Anticancer APIs undergo rigorous testing and adhere to stringent regulatory guidelines before being approved for clinical use.
Due to their critical role in cancer treatment, anticancer drugs are in high demand worldwide. Researchers and pharmaceutical companies continually strive to develop new and more effective APIs in this category to enhance treatment outcomes and minimize side effects. The ongoing advancements in the field of anticancer drug development offer hope for improved cancer therapies and better patient outcomes.
